

32. Scheltens P, Barkhof F, Valk J, et al. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. *Brain* 1992;115:735-48.
33. Pei JJ, Braak E, Braak H, et al. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. *J Alzheimers Dis* 2001;3:41-8.
34. Hoozemans JJ, van Haastert ES, Nijholt DA, et al. The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. *Am J Pathol* 2009;174:1241-51.
35. Bossers K, Wirz KT, Meerhoff GF, et al. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. *Brain* 2010;133:3699-723.
36. Chami L, Buggia-Prevot V, Duplan E, et al. Nuclear factor-kappaB regulates betaAPP and beta- and gamma-secretases differently at physiological and supraphysiological Abeta concentrations. *J Biol Chem* 2012;287:24573-84.
37. Dever TE. Gene-specific regulation by general translation factors. *Cell* 2002;108:545-56.
38. Proud CG. eIF2 and the control of cell physiology. *Semin Cell Dev Biol* 2005;16:3-12.
39. O'Connor T, Sadleir KR, Maus E, et al. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. *Neuron* 2008;60:988-1009.
40. Gupta S, Barrett T, Whitmarsh AJ, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. *EMBO J* 1996;15:2760-70.
41. Kim W, Lee S, Hall GF. Secretion of human tau fragments resembling CSF-tau in Alzheimer's disease is modulated by the presence of the exon 2 insert. *FEBS Lett* 2010;584:3085-8.
42. Kim W, Lee S, Jung C, et al. Interneuronal transfer of human tau between Lamprey central neurons in situ. *J Alzheimers Dis* 2010;19:647-64.
43. Simon D, Garcia-Garcia E, Royo F, et al. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. *FEBS Lett* 2012;586:47-54.
44. Resnick L, Fennell M. Targeting JNK3 for the treatment of neurodegenerative disorders. *Drug Discov Today* 2004;9:932-9.
45. Waetzig V, Herdegen T. Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. *Trends Pharmacol Sci* 2005;26:455-61.
46. Sclip A, Antoniou X, Colombo A, et al. C-Jun N-terminal kinase regulates soluble Abeta oligomers and cognitive impairment in AD mouse model. *J Biol Chem* 2011;286:43871-80.
47. Zhu PJ, Huang W, Kalikulov D, et al. Suppression of PKR promotes network excitability and enhanced cognition by interferon-gamma-mediated disinhibition. *Cell* 2011;147:1384-96.

Correction

Impaired musical ability in people with schizophrenia

There were errors in the degrees and affiliations listed for Sanae Hatada, one of the authors of the paper "Impaired musical ability in people with schizophrenia" (*J Psychiatry Neurosci* 2014;39(2):118-26). S. Hatada has the degrees MED and OTR and is affiliated with the Department of Occupational Therapy, Tosa Rehabilitation College, Kochi, Japan.

We apologize for the errors.